Polycyclo Ring System Having The Hetero Ring As One Of The Cyclos Patents (Class 514/468)
-
Publication number: 20120122943Abstract: Melampomagnolide B is disclosed as a new antileukemic sesquiterpene. A biotin-conjugated derivative of melampomagnolide B was prepared to elucidate its mechanism of action. Prodrugs of Melampomagnolide B are disclosed.Type: ApplicationFiled: October 21, 2011Publication date: May 17, 2012Applicant: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATIONInventors: Peter A. Crooks, Craig T. Jordan, Shanshan Pei, Shama Nasim
-
Publication number: 20120114714Abstract: Disclosed is a pharmaceutical composition for the treatment and/or prevention of erectile dysfunction, comprising (a) a therapeutically effective amount of a compound represented by Formula 1 or 2, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.Type: ApplicationFiled: January 13, 2012Publication date: May 10, 2012Inventors: Taehwan KWAK, Myung-Gyu Park, Sang-Ku You
-
Publication number: 20120115877Abstract: The present invention discloses compositions of facially amphiphilic compounds and their use in methods for treating or reducing cancers in animals, such as humans.Type: ApplicationFiled: August 20, 2011Publication date: May 10, 2012Applicant: POLYMEDIX, INC.Inventors: Richard W. Scott, Dylan Clements, Yongjiang Xu, Haizhong Tang, Carol Mulrooney, Ehab Khalil, Damian Weaver, Xiaodong Fan
-
Publication number: 20120107300Abstract: Cannabinoid compositions and methods of administering said cannabinoid compositions are disclosed. The cannabinoid compositions disclosed herein include compounds which have been strategically selected to eliminate, or least mitigate, one of the negative side effects associated with consuming cannabinoids. A daytime formula includes compounds aimed at nullifying the negative side effects that cannabinoid consumption has on a patient's daily operations and activities. A nighttime formula includes compounds aimed at nullifying the negative side effects that cannabinoid consumption has a patient's sleep.Type: ApplicationFiled: November 1, 2010Publication date: May 3, 2012Inventor: Jeffrey Nathan Schirripa
-
Publication number: 20120107323Abstract: The invention provides compounds capable of treating a subject suffering from or being susceptible to a cell proliferative disorder (especially, cancer), methods of identifying and using the compounds, pharmaceutical compositions and kits thereof.Type: ApplicationFiled: March 12, 2010Publication date: May 3, 2012Applicant: University of FloridaInventors: Steven N. Hochwald, David A. Ostrov, William G. Cance, Elena Kurenova
-
Publication number: 20120101153Abstract: The present invention discloses new rocaglaol derivatives and the use of rocaglaol derivatives to prevent or to limit the cardiotoxicity of an antineoplastic agent, in particular to prevent or to limit the apoptosis of cardiomyocytes induced by such agent.Type: ApplicationFiled: November 24, 2009Publication date: April 26, 2012Applicant: Universite De StrasbourgInventors: Laurent Desaubry, Gunsel Canan Desaubry, Thierry Cresteil, Gülen Türkeri
-
Publication number: 20120101091Abstract: The present application provides compounds of formula I wherein X, Y, R2, n, R5 and R6 are defined herein, useful as inhibitors of the hepatitis C virus NS5B polymerase The present application also provides pharmaceutical compositions containing said compounds, methods of using said compounds as pharmaceuticals alone or with other antiviral agent in the treatment of a hepatitis C viral infection in a mammal having or at risk of having the infection.Type: ApplicationFiled: October 1, 2009Publication date: April 26, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Pierre Beaulieu, Pierre Bonneau, René Coulombe, Pasquale Forgione, James Gillard, Araz Jakalian, Jean Rancourt
-
Publication number: 20120100175Abstract: This subject invention is directed to a method for inhibition of cancer cells, comprising administrating an effective amount of a compound of formula I (Sesquiterpene lactones, antrocin) or pharmaceutically acceptable salts thereof, together with a pharmaceutically acceptable carrier, wherein the cancer cells are selected from colorectal cancer cells, liver cancer cells, lung cancer cells or breast cancer cells.Type: ApplicationFiled: December 27, 2011Publication date: April 26, 2012Applicant: CHAOYANG UNIVERSITY OF TECHNOLOGYInventors: Yew-Min Tzeng, Tien-Shen Yang, Chi-Tai Yeh
-
Publication number: 20120088825Abstract: Disclosed herein are compounds of Formula I as disclosed herein, methods of modulating the activity of an estrogen receptor and methods of treating a disorder associated with estrogen receptors.Type: ApplicationFiled: December 14, 2011Publication date: April 12, 2012Applicant: ACADIA PHARMACEUTICALS INC.Inventors: Roger OLSSON, Lene HYLDTOFT, Magnus GUSTAFSSON, Brigitte WINTHER LUND
-
Publication number: 20120088826Abstract: An industrial process for production of high-purity optically active amine derivatives in high yield while inhibiting the formation of by-products, which comprises subjecting (E)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-ylidene)ethylamine to asymmetric reduction, catalytically reducing the obtained product at a reaction temperature of 40 to 100° C. and a pH of 3 to 9, subjecting the obtained (S)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethylamine to propionylation, and then crystallizing the reaction mixture.Type: ApplicationFiled: December 14, 2011Publication date: April 12, 2012Applicant: Takeda Pharmaceutical Company LimitedInventors: Shinichi Urayama, Eigo Mutou, Atsushi Inagaki, Takashi Okada, Shigeharu Sugisaki
-
Publication number: 20120083527Abstract: The present disclosure relates generally to compositions and methods for treating cancer. In some aspects, novel spirohexenolides and methods of using and producing them are described.Type: ApplicationFiled: April 16, 2010Publication date: April 5, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Michael D. Burkart, James J. La Clair, Minjin Kang, Brian D. Jones, Alexander L. Mandel, Wei-Luen Yu, Justin C. Hammons
-
Publication number: 20120083488Abstract: A compound represented by the general Formula (I) below, or a salt or solvate thereof, which is useful as an ALK inhibitor, and is useful for prophylaxis or treatment of a disease accompanied by abnormality in ALK, for example, cancer, cancer metastasis, depression or cognitive function disorder: (meanings of the symbols that are included in the formula are as given in the specification).Type: ApplicationFiled: June 9, 2010Publication date: April 5, 2012Inventors: Kazutomo Kinoshita, Kohsuke Asoh, Noriyuki Furuichi, Toshiya Ito, Hatsuo Kawada, Nobuya Ishii, Hiroshi Sakamoto, WooSang Hong, MinJeong Park, Yoshiyuki Ono, Yashuharu Kato, Kenji Morikami, Takashi Emura, Nobuhiro Oikawa
-
Publication number: 20120083526Abstract: The present invention relates in general to the field of organic chemistry and in particular to the preparation of 1-(2,3-dihydrobenzofuran-4-yl)ethanone, an intermediate in preparation of (S)—N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide, i.e. ramelteon.Type: ApplicationFiled: April 6, 2010Publication date: April 5, 2012Applicant: LEK PHARMACEUTICALS D.D.Inventor: Jerome CLuzeau
-
Publication number: 20120071523Abstract: The instant invention provides novel benzofuran-4,5-diones and pharmaceutical compositions thereof useful for inhibiting PDF and for treating proliferative and infectious diseases. Compounds may be selective for eukaryotic (e.g., human) PDF or prokaryotic PDF.Type: ApplicationFiled: May 5, 2010Publication date: March 22, 2012Applicant: Sloan-Kettering Institute for Cancer ResearchInventors: Hakim Djaballah, Christophe Antczak
-
Publication number: 20120071539Abstract: Methods and compositions comprising chemical compounds that modulate the silencing of a polynucleotide of interest in a cell are provided. Such chemical compounds when used in combination with an appropriate silencing element can be used to modulate (increase or decrease) the level of the polynucleotide targeted by the silencing element. Methods of using such compositions both in therapies involving RNAi-mediated suppression of gene expression, as well as, in vitro methods that allow for the targeted modulation of expression of a polynucleotide of interest are provided. Pharmaceutical or cosmetic compositions comprising such compounds and silencing elements also are disclosed. Methods for screening a compound of interest for the ability to modulate the activity of a heterologous silencing element also are provided.Type: ApplicationFiled: December 12, 2007Publication date: March 22, 2012Applicant: Emory UniversityInventor: Peng Jin
-
Patent number: 8138187Abstract: The invention relates to substituted heteroaryl derivatives, to methods for the production thereof, to medicaments containing said compounds and to the use of substituted heteroaryl derivatives for producing medicaments.Type: GrantFiled: January 15, 2009Date of Patent: March 20, 2012Assignee: Gruenenthal GmbHInventors: Saskia Zemolka, Stefan Schunk, Werner Englberger, Babette-Yvonne Kögel, Klaus Linz, Hans Schick, Helmut Sonnenschein, Heinz Graubaum, Claudia Hinze
-
Publication number: 20120046242Abstract: The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/?-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/?-catenin signaling and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/?-catenin pathway in a subject is also discussed.Type: ApplicationFiled: December 21, 2009Publication date: February 23, 2012Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, UNIVERSITY OF WASHINGTONInventors: Randall T. Moon, Travis L. BIechele, Nathan D. Camp, Stephen Haggarty, Daniel Fass
-
Publication number: 20120045519Abstract: Methods for treating melanoma in a subject in need thereof are disclosed. The method comprises administering to the subject a composition comprising a therapeutically effective amount of deoxyelephantopin or an analogue thereof; and a pharmaceutically acceptable carrier. Methods of inhibiting proliferation, migration and/or metastasis of melanoma cells in a subject in need thereof are also disclosed. Also disclosed are methods for reducing side effects of an anti-cancer agent in a subject in need thereof.Type: ApplicationFiled: August 19, 2011Publication date: February 23, 2012Applicant: Academia SinicaInventors: Lie-Fen SHYUR, Wen-Wan Chao, Ya-Wen Cheng
-
Publication number: 20120040956Abstract: The invention relates to cyclopentabenzofuran derivatives for the treatment and/or prophylaxis of angiogenesis-related disorders.Type: ApplicationFiled: June 3, 2011Publication date: February 16, 2012Applicant: INTERMED DISCOVERY GMBHInventors: Philipp WABNITZ, Matthias Gehling, Thomas Henkel, M. Lienhard Schmitz
-
Publication number: 20120035170Abstract: This invention concerns novel substituted unsaturated tetracyclic tetrahydrofuran derivatives with binding affinities towards serotonine receptors, in particular 5-HT2A and 5-HT2C receptors, and towards dopamine receptors, in particular dopamine D2 receptors and with norepinephrine reuptake inhibition properties, pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in claim 1.Type: ApplicationFiled: August 22, 2011Publication date: February 9, 2012Inventors: José Maria Núñez, Antonius Adrianus Hendrikus Petrus Megens, Andrés Avelino Trabanco-Suárez
-
Publication number: 20120028892Abstract: The invention is directed to a compound according to formula (I). The compounds of formula (I) include prodrugs, pharmaceutically acceptable salts, stereoisomer mixtures, and enantiomers thereof. The invention is also directed to a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically acceptable carrier and to methods for treating diabetes by administering such a pharmaceutical composition alone or in combination with other therapeutic agents. The invention is also directed to inhibitors of fructose-1,6-bisphosphatase.Type: ApplicationFiled: February 4, 2010Publication date: February 2, 2012Applicant: Trustees of Boston CollegeInventors: Evan R. Kantrowitz, Sabrina Heng
-
Publication number: 20120022153Abstract: A novel compound derived from the culture product of an actinomycete and having an antitumor activity is provided. Provided is a compound represented by any one of formulas (I), (II) and (III) or an optical isomer thereof or a pharmaceutically acceptable salt thereof which can be isolated from the culture fluid of an actinomycete which belongs to the genus Streptomyces, wherein R1, R2, R5 and R6 each independently represent a hydrogen atom, a methyl group, a hydroxymethyl group, a hydroxyl group, or a double bond by which R1 and R2 or R5 and R6 are bonded; R3, R4, R7 and R8 each independently represent a methyl group or a hydroxymethyl group; and R9 represents a hydrogen atom or a hydroxyl group.Type: ApplicationFiled: March 24, 2010Publication date: January 26, 2012Applicant: NIPPON SUISAN KAISHA, LTD.Inventors: Seizo Sato, Fumie Iwata, Shoichi Yamada, Jiro Takeo, Akihisa Abe, Hiroyuki Kawahara
-
Publication number: 20120020954Abstract: Provided are methods and kits for classifying a subject as being more likely to have benign multiple sclerosis (BMS) or as being more likely to have typical relapsing remitting multiple sclerosis (RRMS). Classification of multiple sclerosis disease course is performed by comparing a level of expression of at least one gene involved in the RNA polymerase I pathway in a cell of the subject to a reference expression data of said at least one gene obtained from a cell of at least one subject pre-diagnosed as having BMS and/or from a cell of at least one subject pre-diagnosed as having typical RRMS, thereby classifying the subject as being more likely to have BMS or as being more likely to have typical RRMS. Also provided are methods of diagnosing and treating multiple sclerosis and methods of monitoring treatment efficiency.Type: ApplicationFiled: March 28, 2010Publication date: January 26, 2012Inventors: Anat Achiron, Michael Gurevich
-
Publication number: 20110319389Abstract: The present invention relates to methods for the treatment or prevention of fatigue associated with disordered sleep, for example, in multiple sclerosis, fibromyalgia, Fabry's disease, Parkinson's disease, or traumatic brain injury, using cyclobenzaprine The present invention further relates to a biomarker for the therapeutic effects of a cyclobenzaprine treatment.Type: ApplicationFiled: June 9, 2011Publication date: December 29, 2011Applicant: TONIX PHARMACEUTICALS, INC.Inventors: Seth Lederman, Herb Harris
-
Publication number: 20110319485Abstract: The present invention provides a composition having anti-Helicobacter pylori activity and the composition contains ovatodiolide with effective dosage to inhibit Helicobacter pylori growth or ovatodiolide related substances and its acceptable carrier. The present invention also provides a method for treating ovatodiolide to produce a composition for killing Helicobacter pylori. The present invention also provides an application of ovatodiolide to produce pharmaceuticals for curing gastric ulcers. The ovatodiolide isolated from natural material extract has been confirmed able to inhibit the growth of Helicobacter pylori or to kill Helicobacter pylori. The ovatodiolide can be used in various industries related to the inhibiting or killing of Helicobacter pylori with few side effects and is easy to obtain with low cost.Type: ApplicationFiled: April 29, 2011Publication date: December 29, 2011Applicant: Yushen Biotechnology & Medical Co, Ltd.Inventors: Hsiu-Man Lien, Chin-Jui Tseng, Ya-Yun Lai, Chao-Lu Huang, Chia-Chang Chen
-
Publication number: 20110312903Abstract: Methods for fluorinating organic compounds are described herein.Type: ApplicationFiled: November 20, 2009Publication date: December 22, 2011Inventors: Tobias Ritter, Takeru Furuya, PingPing Tang
-
Publication number: 20110301233Abstract: Novel polyisoprenylated benzophenone derivatives isolated from the plant Garcinia paucinervis. Among these new compounds, paucinones A-C (Compounds 1-3) contains an unexpected cyclohexane-spiro-tetrahydrofuran moiety. A 1-methylene-3,3-dimethylcyclohexane group never reported before was found in the structure of paucinone D (Compound 4). Structures of these compounds were elucidated with spectroscopic evidence. The relative stereochemistry of 1-4 was determined by NOESY correlations. These compounds a potent ability to activate caspase-3 in HeLa-C3 cells within 72 hours at a low concentration and significant cytotoxicity against HeLa-C3 cells.Type: ApplicationFiled: June 4, 2010Publication date: December 8, 2011Inventors: XUE-MEI GAO, Ting Yu, Kathy Qian Luo, Hong Xi Xu
-
Patent number: 8067462Abstract: A compound having the structure of the formula (genus of compound 1 excluding Tashironin or Debenzoyltashironin) and methods of the same.Type: GrantFiled: December 20, 2005Date of Patent: November 29, 2011Assignee: The Trustees of Columbia University in the City of New YorkInventors: Samuel J. Danishefsky, Silas P. Cook
-
Publication number: 20110288166Abstract: Disclosed are compounds based on C- and D-ring modifications of triptolide and hydroxylated triptolide, for use in therapy, such as antiproliferative, anticancer, and immunosuppressive therapy.Type: ApplicationFiled: February 4, 2010Publication date: November 24, 2011Inventor: John H. Musser
-
Patent number: 8058288Abstract: The present invention relates to inhibitors of 11-? hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-? hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.Type: GrantFiled: June 17, 2010Date of Patent: November 15, 2011Assignee: Incyte CorporationInventors: Wenqing Yao, Jincong Zhuo, Meizhong Xu, Colin Zhang, Brian W. Metcalf, Chunhong He, Ding-Quan Qian
-
Patent number: 8048914Abstract: Methods for extraction, isolation, and purification of therapeutically useful compounds from Tripterygium wilfordii are described. Extraction steps employing aqueous base and a hydrocarbon solvent, respectively, are found to increase the efficiency of the process and reduce the amount of material that must be removed by chromatography.Type: GrantFiled: February 7, 2005Date of Patent: November 1, 2011Assignee: Pharmagenesis, Inc.Inventors: Jinhua An, Rensheng Xu, John H. Musser
-
Publication number: 20110263700Abstract: This subject invention is directed to a pharmaceutical composition for the inhibition of cancer cells, comprising an effective amount of a compound of formula I (Sesquiterpene lactones, antrocin) or pharmaceutically acceptable salts thereof, together with a pharmaceutically acceptable carrier.Type: ApplicationFiled: April 26, 2010Publication date: October 27, 2011Applicant: CHAOYANG UNIVERSITY OF TECHNOLOGYInventors: Yew-Min Tzeng, Tien-Shen Yang, Chi-Tai Yeh
-
Publication number: 20110251216Abstract: The present invention relates to therapeutic targets for cancer. In particular, the present invention relates to small molecules and nucleic acids that target EZH2 expression in cancer (e.g., prostate cancer, breast cancer, other solid tumors, multiple myeloma).Type: ApplicationFiled: February 10, 2011Publication date: October 13, 2011Applicant: The Regents of The University of MichiganInventors: Arul M. Chinnaiyan, Sooryanaryana Lnu, Qi Cao
-
Publication number: 20110250166Abstract: The present invention relates to a combined preparation comprising at least one rocaglamide derivative and at least one apoptosis inducing agent, preferably from the group of substances comprising agents inducing the extrinsic apoptotic pathway, antiproliferative agents and agents which induce apoptosis in T-cells by activation induced cell death (AICD) for the treatment of cancer.Type: ApplicationFiled: November 20, 2009Publication date: October 13, 2011Applicant: DKFZ DEUTSCHES KREBSFORSCHUNGSZENTRUMInventors: Min Li-Weber, Peter H. Krammer
-
Publication number: 20110251236Abstract: Therapeutic agents for treatment of Galactosemia and disorders thereof, and other enzyme related disorders thereof are identified. The compounds inhibit galactokinase (GALK) and other kinase activity and are identified by a high throughput screening assay.Type: ApplicationFiled: August 14, 2008Publication date: October 13, 2011Applicant: University of MiamiInventors: Kent Lai, Klass Jan Wierenga, Manshu Tang
-
Publication number: 20110245206Abstract: This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.Type: ApplicationFiled: February 23, 2011Publication date: October 6, 2011Inventors: XIN JIANG, XIAOFENG LIU, JACK GREINER, STEPHEN S. SZUCS, MELEAN VISNICK
-
Patent number: 8030347Abstract: The present application relates to a novel cyclopenta[b]benzofuran derivatives, processes for their preparation and their use for the manufacture of medicaments, in particular for the prophylaxis and/or therapy of acute or chronic disorders characterized by elevated cellular stress, by local or systemic inflammatory processes or by hyperproliferation.Type: GrantFiled: May 14, 2005Date of Patent: October 4, 2011Assignee: Bayer HealthCare AGInventors: Nicole Diedrichs, Thomas Fahrig, Irene Gerlach, Jaques Ragot, Joachim Schuhmacher, Kai Thede, Ervin Horváth
-
Publication number: 20110229464Abstract: Pharmaceutical compositions and methods for treating and/or preventing age-related macular degeneration with melatonin analogues are provided.Type: ApplicationFiled: June 17, 2009Publication date: September 22, 2011Inventors: David Baron, Keisuke Hirai, Yasushi Shintani, Osamu Uchikawa
-
Patent number: 8022102Abstract: This invention concerns novel substituted unsaturated tetracyclic tetrahydrofuran derivatives with binding affinities towards serotonine receptors, in particular 5-HT2A and 5-HT2C receptors, and towards dopamine receptors, in particular dopamine D2 receptors and with norepinephrine reuptake inhibition properties, pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substitutents are defined as in Claim 1.Type: GrantFiled: June 21, 2005Date of Patent: September 20, 2011Assignee: Janssen Pharmaceutica, NVInventors: José Maria Cid-Núñez, Antonius Adrianus Hendrikus Petrus Megens, Andrés Avelino Trabanco-Suárez
-
Patent number: 8022055Abstract: The invention relates to novel betulinic acid derivatives of formula (I), wherein R is C(?CH2)CH3 or CH(CH3)2; R2 together with the adjacent carbonyl group forms a carboxylic acid, carboxylic acid ester or amide or substituted amide; R3 or R4 are hydrogen or aryl with the proviso that both are not independently hydrogen or alkyl or R3 and R4 are combined together to form an aryl ring optionally substituted with a group X, wherein X is selected from halogen, alkyl, cyano, nitro, alkoxy, amino or substituted amine; Y is N or O; and R1 is zero when Y is O, and R1 is hydrogen, alkyl or aryl alkyl when Y is N, useful for inhibition of tumor cancer cells.Type: GrantFiled: December 29, 2005Date of Patent: September 20, 2011Assignee: Dabur Pharma LimitedInventors: Rama Mukherjee, Sanjay Kumar Srivastava, Mohammad Jamshed Ahmed Siddiqui, Manu Jaggi, Anu T. Singh, Anand Vardhan, Manoj Kumar Singh, Praveen Rajendran, Hemant Kumar Jajoo, Anand C. Burman, Vivek Kumar, Nidhi Rani, Shiv Kumar Agarwal
-
Publication number: 20110224293Abstract: Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto.Type: ApplicationFiled: November 22, 2010Publication date: September 15, 2011Applicant: SANOFI-AVENTISInventors: Davide RADZIK, Martin VAN EICKELS, Nacéra HAMDANI, Christophe GAUDIN
-
Publication number: 20110224146Abstract: The present invention provides methods of therapy of cognitive deficits associated with a central nervous system disorder or condition, methods of enhancing cognitive performance and methods for repeated stimulation of neuronal activity or a pattern of neuronal activity, such as that underlying a specific neuronal circuit(s). The methods comprise combining cognitive training protocols and a general administration of CREB pathway-enhancing agents.Type: ApplicationFiled: May 23, 2011Publication date: September 15, 2011Inventors: Timothy P. Tully, Filippo Cavalieri
-
Publication number: 20110217301Abstract: The present invention relates to a method for treating and screening for compounds for the treatment of sepsis. More specifically, the treatment and screening methods are based on the discovery that granzyme B containing platelets (GzmB-platelet) causes apoptosis by direct contact with cells.Type: ApplicationFiled: April 6, 2011Publication date: September 8, 2011Applicant: THE CHILDREN'S RESEARCH INSTUTEInventor: ROBERT J. FREISHTAT
-
Publication number: 20110218143Abstract: The invention generally provides compositions and methods for the repair or regeneration of a tissue or organ in need thereof.Type: ApplicationFiled: November 20, 2008Publication date: September 8, 2011Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATIONInventors: Shalesh Kaushal, Mani Annamalai
-
Patent number: 8003692Abstract: Fluorene-based molecules and their derivatives are described in compositions for the treatment of intestinal fluid loss.Type: GrantFiled: June 13, 2008Date of Patent: August 23, 2011Assignees: Board of Regents, The University of Texas System, Mission Pharmacal Co.Inventors: Catherine H. Schein, Johnny W. Peterson, Scott R. Gilbertson, Deliang Chen, Maria Estrella-Jimenez, Mary A. Walter, Jian Gao
-
Patent number: 8003691Abstract: The present invention relates to an antiviral and antibacterial pharmaceutical composition comprising cantharidic anhydride-essential oil preparation as effective ingredient and method for preparing thereof. The cantharidic anhydride-essential oil preparation is prepared by dissolving cantharidic anhydride at appropriate temperatures. The clinical trials demonstrate that the cantharidic anhydride-essential oil preparation is effective in the treatment of tuberculosis and various viruses infected diseases. Furthermore, a series of local formulations for external use for treatment and prevention of virus infections can be prepared from the said cantharidic anhydride-essential oil preparations.Type: GrantFiled: November 22, 2002Date of Patent: August 23, 2011Inventor: Wei Wang
-
Patent number: 7989498Abstract: The present invention relates to compounds which inhibit IMPDH. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting IMPDH enzyme activity and consequently, may be advantageously used as therapeutic agents for IMPDH mediated processes. This invention also relates to methods for inhibiting the activity of IMPDH using the compounds of this invention and related compounds.Type: GrantFiled: September 25, 2003Date of Patent: August 2, 2011Assignee: Vertex Pharmaceuticals IncorporatedInventors: Jeffrey O Saunders, Daniel Elbaum, Perry M Novak, Douglas Naegele, Randy S Bethiel, Steven M Ronkin, Michael C Badia, Catharine Frank, Dean P Stamos, William Walters, David Pearlman
-
Publication number: 20110184058Abstract: The present invention describes the preparation of 6,7-dihydro-1H-indeno[5,4-b]furan-8(2H)-one, a key intermediate in preparation of ramelteon. The present invention also describes further preceding intermediate compounds useful for the synthesis of 6,7-dihydro-1H-indeno[5,4-b]furan-8(2H)-one.Type: ApplicationFiled: July 13, 2009Publication date: July 28, 2011Applicant: Lek Pharmaceuticals D.D.Inventor: Jerome Cluzeau
-
Publication number: 20110177085Abstract: The present invention relates to bitter-taste receptors and their role in bitter taste transduction. The invention also relates to assays for screening molecules that modulate, e.g. suppress or block, bitter taste transduction, or enhance bitter taste response.Type: ApplicationFiled: March 25, 2011Publication date: July 21, 2011Inventors: Bernd Bufe, Thomas Hofmann, Dietmar Krautwurst, Christina Kuhn, Wolfgang Meyerhof
-
Publication number: 20110178065Abstract: Provided herein are inhibitors of CYP17 enzyme. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat androgen-dependent diseases, disorders and conditions.Type: ApplicationFiled: January 13, 2011Publication date: July 21, 2011Applicant: BIOMARIN PHARMACEUTICAL INC.Inventors: Daniel Chu, Bing Wang, Tao Ye